Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $501000.0.

  • Janux Therapeutics' Depreciation & Amortization (CF) fell 176.47% to $501000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 28.86%. This contributed to the annual value of $2.1 million for FY2024, which is 537.08% up from last year.
  • Latest data reveals that Janux Therapeutics reported Depreciation & Amortization (CF) of $501000.0 as of Q3 2025, which was down 176.47% from $541000.0 recorded in Q2 2025.
  • Janux Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $541000.0 for Q2 2025, and its period low was $9000.0 during Q1 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $471000.0 (2023), whereas its average is $343684.2.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first soared by 260000.0% in 2021, then tumbled by 357.82% in 2024.
  • Janux Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $64000.0 in 2021, then surged by 529.69% to $403000.0 in 2022, then surged by 31.76% to $531000.0 in 2023, then fell by 3.58% to $512000.0 in 2024, then dropped by 2.15% to $501000.0 in 2025.
  • Its last three reported values are $501000.0 in Q3 2025, $541000.0 for Q2 2025, and $519000.0 during Q1 2025.